Lupin , a global pharmaceutical leader, has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company to commercialise Vonoprazan Tablets in India.
In a press statement on Wednesday, the company informed that the novel gastrointestinal drug, marketed under the brand name Lupivon, will be available in 10 mg and 20 mg strengths.
The agreement grants Lupin the right to introduce Vonoprazan, an innovative treatment for Acid Peptic Disorders (APD), which include Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD). These conditions are highly prevalent in India, with GERD affecting 5 per cent to 28.5 per cent of the population, while PUD affects approximately 8 per cent.
Rajeev Sibal, President of India Region Formulations at Lupin, said, “We are excited to bring Vonoprazan to the Indian market. This novel treatment option strengthens our gastroenterology portfolio and aligns with our commitment to addressing unmet medical needs.”
